Trial.source,Drug_1,canSAR_target_1,Drug_1_target_uniprots,InChI_1,InChIKey_1,SMILES_1,Drug_2,canSAR_target_2,Drug_2_target_uniprots,InChI_2,InChIKey_2,SMILES_2,Patient.population,Disease,Phase,PMID,Results,NCT.Number,Title,Recruitment,Study.Results,Conditions,Interventions,Sponsor.Collaborators,Gender,Age,Enrollment,Funded.Bys,Study.Types,Study.Designs,Other.IDs,Acronym,Primary.Completion.Date,Outcome.Measures,URL
clinicaltrials.gov,necitumumab,NA,P00533,,,,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,,lung cancers,Phase 1,NA,,NCT02411591,A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC),"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis",Drug: Necitumumab|Drug: Abemaciclib,Eli Lilly and Company,All,"18 Years and older __ (Adult, Senior)",70,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,15573|I4X-MC-JFCU,null,"June 23, 2017","Number of Participants with Abemaciclib Dose Limiting Toxicities (DLTs)|Progression Free Survival (PFS) Rate at Three Months|Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])|Pharmacokinetics (PK): Predose Concentration (Cmin) of Necitumumab and Abemaciclib|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab and Abemaciclib|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Abemaciclib|Disease Control Rate (DCR): Defined as Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD)|Overall Survival",https://ClinicalTrials.gov/show/NCT02411591
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 1,NA,,NCT01574937,XL-184+Abiraterone in Post-Chemo CRPC,"Active, not recruiting",No Results Available,Prostate Cancer,Drug: Cabozantinib|Drug: Abiraterone,Dana-Farber Cancer Institute,Male,"18 Years and older __ (Adult, Senior)",27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,11-441,null,Nov-10,Maximum Tolerated Dose|Definition of a Dosing Regimen,https://ClinicalTrials.gov/show/NCT01574937
clinicaltrials.gov,onapristone,319776,P06401,"InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1",IEXUMDBQLIVNHZ-YOUGDJEHSA-N,CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 1/2,NA,,NCT02049190,Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer,Recruiting,No Results Available,Prostate Cancer|Metastatic Prostate Cancer|Androgen-independent Prostate Cancer|Recurrent Prostate Cancer,Drug: onapristone|Drug: abiraterone,Arno Therapeutics,Male,"18 Years and older __ (Adult, Senior)",75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ARN-AR18-CT-102,null,Jun-13,"Dose limiting toxicities related to onapristone or the combination of onapristone and abiraterone utilizing a day 57 safety cut off and based on CTCAE v4|Response to onapristone or the combination of onapristone and abiraterone|Safety and tolerability of extended-release onapristone tablets BID|PK of onapristone, mono-demethylated onapristone and other metabolites in plasma and urine",https://ClinicalTrials.gov/show/NCT02049190
clinicaltrials.gov,sipuleucel-T,NA,,,,,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 2,NA,,NCT01487863,Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer Metastatic|Hormone Refractory Prostate Cancer|Castration-resistant Prostate Cancer,Biological: sipuleucel-T|Drug: abiraterone acetate,Dendreon,Male,"18 Years and older __ (Adult, Senior)",69,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Basic Science,P11-3,null,Apr-12,Cumulative CD54 Upregulation Ratio Between the Cohorts.,https://ClinicalTrials.gov/show/NCT01487863
clinicaltrials.gov,AZD6738,NA,,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,leukemia,Phase 1/2,NA,,NCT03328273,A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),Recruiting,No Results Available,Chronic Lymphocytic Leukemia,Drug: AZD6738|Drug: acalabrutinib,Acerta Pharma BV,All,"18 Years and older ï_ (Adult, Senior)",62,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACE-CL-110,null,Number of participants experiencing dose-limiting toxicities,,https://ClinicalTrials.gov/show/NCT03328273
clinicaltrials.gov,pembrolizumab,NA,Q15116,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,bladder cancers,Phase 2,NA,,NCT02351739,Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer,"Active, not recruiting",No Results Available,Metastatic Urothelial Carcinoma,Drug: pembrolizumab|Drug: ACP-196 in combination with pembrolizumab,Acerta Pharma BV|Merck Sharp & Dohme Corp.,All,"18 Years and older __ (Adult, Senior)",75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,ACE-ST-005,KEYNOTE143,Nov-13,To determine the overall response rate (ORR) of pembrolizumab monotherapy and the combination of ACP-196 and pembrolizumab in subjects,https://ClinicalTrials.gov/show/NCT02351739
clinicaltrials.gov,pembrolizumab,NA,Q15116,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,lung cancers,Phase 2,NA,,NCT02448303,Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Pembrolizumab|Drug: Acalabrutinib,Acerta Pharma BV|Merck Sharp & Dohme Corp.,All,"18 Years and older __ (Adult, Senior)",74,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ACE-ST-007,KEYNOTE166,May-13,The overall response rate (ORR) of pembrolizumab monotherapy and the combination of acalabrutinib and pembrolizumab in subjects with recurrent or metastatic NSCLC,https://ClinicalTrials.gov/show/NCT02448303
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,ACP-319,NA,,,,,,lymphoma;multiple myeloma,Phase 1/2,NA,,NCT02328014,"ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",Recruiting,No Results Available,Non-hodgkins Lymphoma|Multiple Myeloma|B-All,Drug: ACP-196 and ACP-319|Drug: ACP-196 and ACP-319,Acerta Pharma BV,All,"18 Years and older __ (Adult, Senior)",126,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ACE-LY-001,null,Jul-13,Incidence of adverse events from the combination of ACP-196 and ACP-319|Overall response rate of the combination of ACP-196 and ACP-319,https://ClinicalTrials.gov/show/NCT02328014
clinicaltrials.gov,BI 836845,NA,,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,lung cancers,Phase 1,NA,,NCT02191891,Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC),Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: BI 836845|Drug: afatinib,Boehringer Ingelheim,All,"18 Years and older __ (Adult, Senior)",34,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1280.16,null,"March 2, 2018","Maximum tolerated dose (MTD) of BI 836845 in combination with afatinib - part A|Dose limiting toxicity (DLT) during the first treatment course - part A|Objective response (OR), defined as complete response (CR) or partial response (PR)|Disease control (DC), defined as complete response (CR), partial response (PR) or stable disease (SD)|Time to objective response, defined as the duration of time from the date of first treatment administration until objective response|Duration of objective response, defined as the duration of time from first objective response to the date of first objective tumour progression or death due to any cause",https://ClinicalTrials.gov/show/NCT02191891
clinicaltrials.gov,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,advanced solid cancers,Phase 1,NA,,NCT02020577,Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours,Completed,Has Results,Neoplasms,Drug: Cetuximab( erbitux__)|Drug: Afatinib,Boehringer Ingelheim,All,"18 Years and older __ (Adult, Senior)",58,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1200.122|2012-005230-10,null,Dec-10,MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).|Dose Limiting Toxicities During Cycle 1|MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).|Dose Limiting Toxicities During All Treatment Cycles|Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)|Best Overall Response|Objective Response|Disease Control Rate|Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib),https://ClinicalTrials.gov/show/NCT02020577
clinicaltrials.gov,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,head and neck cancers,Phase 2,NA,,NCT02979977,Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck,Recruiting,No Results Available,Squamous Cell Cancers of the Head and Neck,Drug: cetuximab|Drug: afatinib,Yale University|National Comprehensive Cancer Network|Boehringer Ingelheim,All,"18 Years and older __ (Adult, Senior)",50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1608018260,null,Nov-14,Tumor shrinkage|Progression-free survival in weeks|Overall survival in months|Duration of response in weeks|Toxicity assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,https://ClinicalTrials.gov/show/NCT02979977
clinicaltrials.gov,trastuzumab,4,P04626,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,breast cancers,Phase 1,NA,,NCT00950742,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin__ in Patients With HER2-positive Advanced Breast Cancer.,Completed,Has Results,Breast Neoplasms,Drug: Trastuzumab|Drug: BIBW 2992,Boehringer Ingelheim,Female,"18 Years and older __ (Adult, Senior)",18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1200.68|2009-010003-89,null,Sep-09,"Number of Participants With Dose Limiting Toxicities (DLT)|Maximum Tolerated Dose (MTD) of Afatinib in Combination With Herceptin(R)|Number of Patients With Objective Response (OR)|Number of Patients With Best Overall Response|Progression Free Survival (PFS)|Summary of Concentration of Afatinib in Plasma|Time From Dosing to the Maximum Concentration of Afatinib in Plasma at Steady State (Tmax,ss)|Summary of Concentration of Herceptin in Plasma",https://ClinicalTrials.gov/show/NCT00950742
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,afuresertib,1081472,P31751;Q9Y243;P31749,"InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1",AFJRDFWMXUECEW-LBPRGKRZSA-N,Cn1ncc(Cl)c1c2cc(sc2Cl)C(=O)N[C@H](CN)Cc3cccc(F)c3,,multiple myeloma;advanced solid cancers,Phase 1,NA,,NCT01476137,A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers,Completed,No Results Available,Cancer,Drug: GSK1120212|Drug: GSK2110183,GlaxoSmithKline,All,"18 Years and older __ (Adult, Senior)",20,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,115829,null,Feb-09,"Part 1: Safety and tolerability in first 4 weeks as determined by the number of patients with adverse events, serious adverse events, dose reductions or delays, withdrawals due to toxicities and changes in lab values and vital signs from baseline|Part 2A: Number of patients whose disease responds to study drugs, as determined by Overall Response Rate (ORR)|Part 2B: Number of patients whose disease responds to study drugs, as determined by Overall response rate (ORR)|Part 1: Safety and tolerability in continuation as determined by the number of patients with adverse events, serious adverse events, dose reductions or delays, withdrawals due to toxicities and changes in lab values and vital signs from baseline|Part 1: Profile of pharmacokinetic parameters following repeat-dose administration of GSK1120212 and GSK2110183 in combination versus repeat-dose administration of monotherapy GSK2110183 and GSK1120212|Part 2A: Number of patients whose disease responds to study drugs, as shown by PFS; duration of response; change from baseline measures in biomarkers in the PI3K/ATK and MAPK pathways; genetic alterations in PI3K/AKT/RAS/RAF pathway|Part 2B: Number of patients whose disease responds to study drugs, as shown by PFS; duration of response; change from baseline measures in biomarkers in the PI3K/ATK and MAPK pathways; genetic alterations in PI3K/AKT/RAS/RAF pathway",https://ClinicalTrials.gov/show/NCT01476137
clinicaltrials.gov,pentostatin,615,P00813,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1",FPVKHBSQESCIEP-JQCXWYLXSA-N,OC[C@H]1O[C@H](C[C@@H]1O)n2cnc3[C@H](O)CNC=Nc23,alemtuzumab,NA,P31358,,,,,lymphoma;leukemia,Phase 2,NA,,NCT00453193,Alemtuzumab and Pentostatin In T-cell Neoplasms,Terminated,Has Results,Lymphoma|Leukemia,Drug: Pentostatin|Drug: Alemtuzumab,M.D. Anderson Cancer Center|Astex Pharmaceuticals|Bayer,All,"18 Years and older __ (Adult, Senior)",26,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0408,null,Feb-06,Number of Participants With Objective Response,https://ClinicalTrials.gov/show/NCT00453193
clinicaltrials.gov,rituximab,16,P11836,,,,alemtuzumab,NA,P31358,,,,,leukemia,Phase 1,NA,,NCT00330252,Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL,Completed,No Results Available,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Alemtuzumab,"Dana-Farber Cancer Institute|Genzyme, a Sanofi Company",All,"18 Years and older __ (Adult, Senior)",29,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05-404,null,Dec-08,"Maximum tolerated dose of alemtuzumab given once weekly|Response rate of combined rituximab and subcutaneous alemtuzumab (complete or partial response)|Dose limiting toxicities defined as non-hematologic toxicity of grade 3 or greater or irreversible grade 2 renal, neurologic or cardiac toxicity or infectious toxicities if grade 4 or greater|Dose limiting toxicities defined as hematologic toxicities of grade 3 or greater neutropenia or thrombocytopenia for greater than 2 weeks OR ANC < 250 or platelets < 20,000|Response rate as measured by Chest/abdominal/pelvic (+/- neck) CT 4 to 8 weeks following conclusion of 8 Weeks of therapy or at time of study withdrawal|Response rate as measured by physical exam of lymph nodes at 4 to 8 weeks following conclusion of 8 Weeks of therapy or at time of study withdrawal, then every 3 months until disease progression",https://ClinicalTrials.gov/show/NCT00330252
clinicaltrials.gov,IMG-7289,NA,,,,,all-trans retinoic acid,273,P10276;P10826;P13631,,,C\C(=C/C=C/C(=C/C(=O)O)/C)\C=C\C1=C(C)CCCC1(C)C,,leukemia,Phase 1,NA,,NCT02842827,"IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies",Recruiting,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: IMG-7289|Drug: All-trans retinoic acid,"Imago BioSciences,Inc.",All,"18 Years and older __ (Adult, Senior)",30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IMG-7289-CTP-101,null,Jun-13,"Safety and tolerability as measured by monitoring of adverse events, changes in physical examinations, vital signs and laboratory parameters|Pharmacokinetic parameters as measured by acute and steady state sampling|The adequacy of the treatment regimen in producing a pharmacodynamic effect as measured by the IWG/Cheson response criteria",https://ClinicalTrials.gov/show/NCT02842827
clinicaltrials.gov,pembrolizumab,NA,Q15116,,,,all-trans retinoic acid,273,P10276;P10826;P13631,,,C\C(=C/C=C/C(=C/C(=O)O)/C)\C=C\C1=C(C)CCCC1(C)C,,skin cancers,Phase 1/2,NA,,NCT03200847,Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,Recruiting,No Results Available,Stage IV Melanoma|Stage III Melanoma|Advanced Melanoma,Drug: Pembrolizumab with All-Trans Retinoic Acid,"University of Colorado, Denver|Merck Sharp & Dohme Corp.",All,"18 Years to 100 Years ï_ (Adult, Senior)",24,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-1080.cc,null,Maximally Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of the combination of pembrolizumab and All-Trans Retinoic Acid|Dose-Limiting Toxicity (DLT) for the combined treatment of pembrolizumab and All-Trans Retinoic Acid for each patient,,https://ClinicalTrials.gov/show/NCT03200847
clinicaltrials.gov,AEB071,367295,Q05513;Q04759;Q02156;O94806;P17252;Q05655;P05129;P05771;P24723;P41743;Q15139,"InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)",OAVGBZOFDPFGPJ-UHFFFAOYSA-N,CN1CCN(CC1)c2nc(C3=C(C(=O)NC3=O)c4c[nH]c5ccccc45)c6ccccc6n2,alpelisib,NA,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,skin cancers,Phase 1,NA,,NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,Recruiting,No Results Available,Uveal Melanoma,Drug: AEB071|Drug: BYL719,Richard D. Carvajal|Columbia University,All,"18 Years and older __ (Adult, Senior)",50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAN4901|CAEB071AUS01T,null,Sep-14,Total maximum tolerated dose (in milligrams) of AEB071 in combination with BYL719|Number of participants with adverse events|Change in area under the curve (AUC) for the combination of AEB071 and BYL719|Change in peak concentration (Cmax) for the combination of AEB071 and BYL719|Number participants who respond to therapy|Change in numerically calculated toxicity burden (0-10)|Mean months of overall survival,https://ClinicalTrials.gov/show/NCT02273219
clinicaltrials.gov,BGJ398,760906,P11362;P22455;P22607;P21802,,,,alpelisib,NA,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,advanced solid cancers,Phase 1,NA,,NCT01928459,Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,Completed,No Results Available,Advanced Solid Tumors|Metastatic Solid Tumors,Drug: BGJ398|Drug: BYL719,Novartis Pharmaceuticals|Novartis,All,"18 Years and older __ (Adult, Senior)",62,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CBGJ398X2102,null,Jul-12,Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719|Safety and tolerability of BGJ398/BYL719 combination at the recommended dose for expansion (RDE)|Overall response rate|Progression free survival|Time vs. concentration profile of BGJ398 and BYL719,https://ClinicalTrials.gov/show/NCT01928459
clinicaltrials.gov,LGH447,NA,,,,,alpelisib,NA,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,multiple myeloma,Phase 1/2,NA,,NCT02144038,Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,Completed,No Results Available,Relapsed and Refractory Multiple Myeloma,Drug: LGH447|Drug: BYL719,Novartis Pharmaceuticals|Novartis,All,"18 Years and older __ (Adult, Senior)",20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CLGH447X2103C|2013-004959-21,null,Sep-11,"Phase Ib: Number of Total Dose-limiting Toxicities (DLT)|Phase II: Overall Response Rate (ORR) as assessed by Investigators|Phase II: Percent change of ORR (Overall Response Rate) between the two arms|Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability.|Determine single and multiple dose Pharmacokinetics (PK) profiles|Changes between pre- and post-treatment levels of pS6RP and 4EBP1 levels in bone marrow aspirates and 4EBP1 in peripheral blood|Phase II: Absolute difference in ORR|Disease Control Rate|Progression Free Survival|Time to response|Duration of Response",https://ClinicalTrials.gov/show/NCT02144038
clinicaltrials.gov,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,alpelisib,NA,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,stomach cancers;oesophageal cancers,Phase 1,NA,,NCT01613950,PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer,Completed,No Results Available,Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein,Drug: AUY922|Drug: BYL719,Novartis Pharmaceuticals|Novartis,All,"18 Years and older __ (Adult, Senior)",18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,CBYL719X2103|2011-005978-40,null,Feb-10,Incidence rate of Dose Limiting Toxicities.|Frequency of adverse events (AEs)|Best Overall Response (BOR) as per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1|Plasma concentration versus time profiles of BYL719 as single agent an in combination with AUY922.|Overall response rate (ORR) as per RECIST version 1.1|Progression free survival (PFS) as per RECIST version 1.1|Overall survival (OS)|Overall survival rate at 6 months (OS6)|Frequency and severity of serious adverse events (SAEs)|Plasma concentration versus time profile of AUY922 as single agent and in combination with BYL719|Plasma concentration versus time profile of the AUY922 metabolite BJP762|Severity of adverse events (AEs),https://ClinicalTrials.gov/show/NCT01613950
clinicaltrials.gov,ETBX-011,NA,,,,,ALT-803,NA,,,,,,thyroid cancers;bowel cancers;ovarian cancers;breast cancers;lung cancers;pancreatic cancers,Phase 1/2,NA,,NCT03127098,"QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",Not yet recruiting,No Results Available,Thyroid Cancer|Colon Cancer|ovarian Cancers|Breast Cancer|Lung Cancer|Pancreatic Cancer,Biological: ETBX-011|Biological: ALT-803,"NantCell, Inc.",All,"21 Years and older __ (Adult, Senior)",150,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment,QUILT-3.040,null,Dec-15,Dose-limiting toxicities and maximum tolerated dose of the ETBX-011 plus ALT-803 combination treatment. (Phase 1b)|Overall treatment-emergent AEs and SAEs [safety and tolerability] and preliminarily evaluate Objective response rate (ORR). (Phase 2)|Preliminarily evaluate Duration of Response (DoR)|Preliminarily evaluate Progressive-free survival (PFS)|Preliminarily evaluate Overall Survival (OS),https://ClinicalTrials.gov/show/NCT03127098
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,alvocidib,262723,P06493;P24941;P11802;Q00534;P50613;P50750,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1",BIIVYFLTOXDAOV-YVEFUNNKSA-N,CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl,,leukemia,Phase 1,NA,,NCT03441555,A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia,Not yet recruiting,No Results Available,Cancer - Acute Myeloid Leukemia,Drug: Venetoclax|Drug: Alvocidib,"AbbVie|Tolero Pharmaceuticals, Inc.",All,"18 Years and older ï_ (Adult, Senior)",44,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M16-186|2017-002531-42,null,Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib|Tmax of venetoclax|Clearance of Alvocidib|AUC0-___ of Alvocidib|Cmax of Venetoclax|Half-life (t1/2) of Alvocidib|AUC0-24 Post-dose of Venetoclax|Cmax of Alvocidib|AUCt Post-dose of Alvocidib|Complete Response (CR) Rate|Combined CR Rate|Objective Response Rate (ORR),,https://ClinicalTrials.gov/show/NCT03441555
clinicaltrials.gov,ganitumab,NA,P08069,,,,AMG 655,NA,,,,,,bowel cancers;lung cancers;ovarian cancers;pancreatic cancers;soft tissue cancers,Phase 1/2,NA,,NCT00819169,"QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors",Terminated,No Results Available,Colorectal Cancer|Locally Advanced|Metastatic Cancer|Non-Small Cell Lung Cancer|ovarian Cancers|Pancreatic Cancer|Sarcoma|Solid Tumors,Biological: AMG 479|Biological: AMG 655,"NantCell, Inc.",All,"16 Years and older __ (Child, Adult, Senior)",89,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20070411|QUILT-3.026,null,Sep-06,Incedence of dose limiting toxicity|Objective response rate|Time to response|Duration of response|Progression free survival|To evaluate anti-AMG 655 antibody formation and anti-AMG 479 antibody formation|To evaluate the PK of AMG 655 and of AMG 479,https://ClinicalTrials.gov/show/NCT00819169
clinicaltrials.gov,JNJ-809,NA,,,,,apalutamide,NA,,,,,,prostate cancers,Phase 2,NA,,NCT02906605,"A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",Withdrawn,No Results Available,"Prostatic Neoplasms, Castration-Resistant",Drug: JNJ-809|Drug: Apalutamide,"Janssen Research & Development, LLC",Male,"18 Years and older __ (Adult, Senior)",0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CR108224|64041809PCR2002|2016-001917-26,null,Aug-14,"Time to Prostate-specific Antigen (PSA) Progression|PSA Doubling Time (PSADT)|Radiographic Progression-free Survival|Time to Unequivocal Clinical Progression|Overall Survival|Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability|Blood Culture and Shedding Profile of JNJ-809 From Cultured Samples of Feces, Urine, and Saliva",https://ClinicalTrials.gov/show/NCT02906605
clinicaltrials.gov,fluzoparib,NA,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,ovarian cancers;breast cancers,Phase 1,NA,,NCT03075462,A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,Recruiting,No Results Available,ovarian Cancers|Triple Negative Breast Cancer,Drug: Fluzoparib|Drug: Apatinib,"Jiangsu HengRui Medicine Co., Ltd.|Beijing Cancer Hospital",Female,"18 Years to 70 Years __ (Adult, Senior)",76,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,FZPL-I-104-OC/BC,null,Nov-15,The type and incidence of adverse events [safety and tolerability]|Objective Response Rate (ORR)|Disease Control Rate (DOR)|Time to Progression (TTP)|Overall Survival (OS)|Cmax|T1/2 (Half-life)|Area under curve (AUC)|V/F|CL/F,https://ClinicalTrials.gov/show/NCT03075462
clinicaltrials.gov,HS-10241,NA,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,advanced solid cancers,Phase 1,NA,,NCT03243643,"Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors",Not yet recruiting,No Results Available,Advanced Cancer,Drug: HS-10241|Drug: Apatinib,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",All,"18 Years to 75 Years __ (Adult, Senior)",80,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other,HS-10241-I-101,HS:Hansoh;,Jun-15,Dose Limiting Toxicities (DLT)|Maximum Tolerated Dose (MTD)|Adverse events and Serious Adverse Events|The measurement of maximum plasma concentration (Cmax)|The measurement of the area under the plasma concentration-time versus time curve(AUC)|The measurement of time of maximum plasma concentration (Tmax)|The measurement of elimination half life (T1/2)|The Measurement of mean retention time (MRT)|The measurement of apparent volume of distribution (Vd)|The measurement of clearance (Cl)|Duration of Response Rate|Progression-Free Survival|Objective Response Rate,https://ClinicalTrials.gov/show/NCT03243643
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,breast cancers,Phase 1/2,NA,,NCT03394287,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced TNBC,Recruiting,No Results Available,Breast Cancer,Drug: SHR-1210|Drug: Apatinib,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Female,"18 Years to 70 Years ï_ (Adult, Senior)",64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHR-1210-APTN-IIT-TNBC,null,MTD (phase 1b)|ORR (phase 2)|Incidence of Treatment-Emergent Adverse Events (phase 1b/2)|DCR (phase 2)|DoR (phase 2)|PFS (phase 2)|12m-OS (phase 2)|CBR (phase 2)|TTR (phase 2)|Frequencies Of Biomarkers,,https://ClinicalTrials.gov/show/NCT03394287
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,liver cancers,Phase 2,NA,,NCT03463876,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC,Recruiting,No Results Available,Hepatocellular Carcinoma,Drug: SHR 1210+apatinib,"Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years and older ï_ (Adult, Senior)",136,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHR-1210-APTN-_—-208-HCC,null,"Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Time to objective response(TTR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).|9-month survival rate|12-month survival rate|Overall survival(OS)|Progression-free survival(PFS)|Safety as measured by the rate of AEs, SAEs and laboratory abnormalities",,https://ClinicalTrials.gov/show/NCT03463876
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,lung cancers,Phase 2,NA,,NCT03083041,A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC),Not yet recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Biological: SHR-1210|Drug: Apatinib,"Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years to 70 Years __ (Adult, Senior)",118,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,SHR-1210-APTN-II-202-NSCLC,null,"February 27, 2018","Part 1: Incidence and grade of adverse events (AEs) and Serious adverse events (SAEs)|Part 2:Objective response rate (ORR) per RECIST 1.1|Part 1: Apatinib plasma concentrations and serum SHR-1210 concentrations|Part 1:Peak Plasma Concentration (Cmax) of Apatinib and SHR-1210|Part 1:Objective response rate (ORR) - RECIST 1.1|Duration of Response (DoR)|Progression-free survival(PFS)|Overall survival rate at 12 months (OSR12)|Part 1: Area under the plasma concentration-time curve from time 0 to 24 hrs, AUC[0-24]",https://ClinicalTrials.gov/show/NCT03083041
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,lung cancers,Phase 2,NA,,NCT03417895,SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy,Not yet recruiting,No Results Available,Small-cell Lung Cancer,Drug: SHR-1210|Drug: Apatinib,"Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years to 70 Years ï_ (Adult, Senior)",135,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHR-1210-II-206,PASSION,Adverse event of part 1|ORR|Adverse event|OS rate|PFS|TTR|DoR|DCR|OS|Immunogenicity,,https://ClinicalTrials.gov/show/NCT03417895
clinicaltrials.gov,ondansetron,2228,P46098,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,aprepitant,471,P25103,"InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1",ATALOFNDEOCMKK-OITMNORJSA-N,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1c3ccc(F)cc3)c4cc(cc(c4)C(F)(F)F)C(F)(F)F,,leukemia,Phase 2,NA,,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,Completed,Has Results,Hematologic Diseases|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia,Drug: Ondansetron|Drug: Aprepitant,M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.,All,"18 Years and older __ (Adult, Senior)",100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-0615|NCI-2009-01517,null,Mar-09,Participant Responses|Treatment Success Rate,https://ClinicalTrials.gov/show/NCT00954941
clinicaltrials.gov,rivaroxaban,245079,P00742,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",KGFYHTZWPPHNLQ-AWEZNQCLSA-N,Clc1ccc(s1)C(=O)NC[C@H]2CN(C(=O)O2)c3ccc(cc3)N4CCOCC4=O,ASA,NA,,,,,,multiple myeloma,Phase 2/3,NA,,NCT03428373,ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.,Not yet recruiting,No Results Available,Multiple Myeloma in Relapse|Multiple Myeloma Progression|Multiple Myeloma Stage II|Multiple Myeloma Stage I|Multiple Myeloma With Failed Remission|Multiple Myeloma Stage III,Drug: Rivaroxaban|Drug: ASA,Lawson Health Research Institute|The Ottawa Hospital|Dalhousie University|St. Boniface General Hospital Research Centre|McMaster University,All,"18 Years to 90 Years ï_ (Adult, Senior)",86,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10014356,RithMM,Thrombosis assessment of patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,https://ClinicalTrials.gov/show/NCT03428373
clinicaltrials.gov,bevacizumab,11,P15692,,,,atezolizumab,NA,Q9NZQ7,,,,,kidney cancers,Phase 2,NA,,NCT02724878,Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,Recruiting,No Results Available,Advanced Non-Clear Cell Kidney Cancer,Drug: Bevacizumab|Drug: Atezolizumab,"Dana-Farber Cancer Institute|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,15-592,null,Sep-15,Overall response rate|Duration of response|Number of participants with treatment-related adverse events assessed by CTCAE version 4.0|Immune related objective response rate|Progression free survival|Overall survival|Function Assessment of Cancer Therapy-Kidney Symptom Index-19 score|Brief Fatigue Inventory score,https://ClinicalTrials.gov/show/NCT02724878
clinicaltrials.gov,BL-8040,NA,P61073,,,,atezolizumab,NA,Q9NZQ7,,,,,leukemia,Phase 1/2,NA,,NCT03154827,"A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study",Not yet recruiting,No Results Available,Acute Myeloid Leukemia,Drug: BL-8040|Drug: Atezolizumab,"BioLineRx, Ltd.|Genentech, Inc.",All,"60 Years and older __ (Adult, Senior)",60,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,BL-8040.AML.202,null,"March 17, 2021",Relapse Free Survival,https://ClinicalTrials.gov/show/NCT03154827
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,atezolizumab,NA,Q9NZQ7,,,,,bladder cancers;kidney cancers;lung cancers;prostate cancers,Phase 1/2,NA,,NCT03170960,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Recruiting,No Results Available,Urothelial Carcinoma|Renal Cell Carcinoma|Non-Small Cell Lung Cancer|Castration-resistant Prostate Cancer,Drug: cabozantinib|Drug: atezolizumab,Exelixis,All,"18 Years and older ï_ (Adult, Senior)",360,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XL184-021,null,Dose Escalation: MTD/Recommended Dose|Dose Expansion: ORR|Incidence and severity of nonserious AEs and SAEs (Safety),,https://ClinicalTrials.gov/show/NCT03170960
clinicaltrials.gov,CDX-1401,NA,,,,,atezolizumab,NA,Q9NZQ7,,,,,lung cancers,Phase 2,NA,,NCT02495636,"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",Withdrawn,No Results Available,Non-Small Cell Lung Cancer,Drug: CDX-1401|Drug: MPDL3280A,Yale University,All,"18 Years and older __ (Adult, Senior)",0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1501015233,null,Jun-13,Objective Response Rate,https://ClinicalTrials.gov/show/NCT02495636
clinicaltrials.gov,CMB305,NA,,,,,atezolizumab,NA,Q9NZQ7,,,,,soft tissue cancers,Phase 2,NA,,NCT02609984,Trial of CMB305 and Atezolizumab in Patients With Sarcoma,"Active, not recruiting",No Results Available,Sarcoma|Myxoid/Round Cell Liposarcoma|Synovial Sarcoma|Metastatic Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Locally Advanced Sarcoma|Liposarcoma,Biological: CMB305|Biological: atezolizumab,"Immune Design|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",88,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,IMDZ-C232,IMDZ-C232,"May 26, 2017","Progression Free Survival|Overall Survival|Safety as Evaluated by Adverse Events, Laboratory Findings and Patient Discontinuations|Progression Free Survival Rates|Best Overall Response Rate",https://ClinicalTrials.gov/show/NCT02609984
clinicaltrials.gov,MV-NIS,NA,,,,,atezolizumab,NA,Q9NZQ7,,,,,lung cancers,Phase 1,NA,,NCT02919449,Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,Recruiting,No Results Available,Recurrent Non-Small Cell Lung Cancer,Biological: MV-NIS|Biological: Atezolizumab,"Vyriad, Inc.",All,"18 Years and older __ (Adult, Senior)",42,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,VYR-MV1-101,null,Dec-14,Maximum Tolerated Dose (MTD) of MV-NIS in combination with Atezolizumab,https://ClinicalTrials.gov/show/NCT02919449
clinicaltrials.gov,obinutuzumab,NA,P11836,,,,atezolizumab,NA,Q9NZQ7,,,,,lymphoma;leukemia,Phase 2,NA,,NCT02846623,Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-Risk Untreated Chronic Lymphocytic Leukemia (CLL),Recruiting,No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Obinutuzumab|Drug: Atezolizumab,"M.D. Anderson Cancer Center|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",72,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,2015-1097|NCI-2017-00183,null,"January 1, 2021",Best Overall Response (OR)|Conversion Rate,https://ClinicalTrials.gov/show/NCT02846623
clinicaltrials.gov,RO6874281,NA,,,,,atezolizumab,NA,Q9NZQ7,,,,,,Phase 2,NA,,NCT03386721,Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors,Recruiting,No Results Available,Solid Tumors,"Drug: RO6874281|Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody",Hoffmann-La Roche,All,"18 Years and older ï_ (Adult, Senior)",40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP40234|2017-003182-94,null,Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Percentage of Participants with Disease Control According to RECIST Version 1.1|Duration of Response (DoR) According to RECIST Version 1.1|Progression-Free Survival (PFS) According to RECIST Version 1.1|Overall Survival (OS)|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants by Programmed Death-Ligand 1 (PD-L1) Status According to Immunohistochemical Methods|Change from Baseline in Density of Cluster of Differentiation (CD) 8 Positive (CD8+) Cells According to Immunohistochemical Methods|Change from Baseline in Density of Cluster of Differentiation 3 Negative (CD3-) Perforin Positive Cells According to Immunohistochemical Methods|Change from Baseline in Density of PD-L1 According to Immunohistochemical Methods,,https://ClinicalTrials.gov/show/NCT03386721
clinicaltrials.gov,RO7198457,NA,,,,,atezolizumab,NA,Q9NZQ7,,,,,skin cancers;lung cancers;bladder cancers;colorectal cancers;breast cancers;kidney cancers;head and neck cancers,Phase 1,NA,,NCT03289962,A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,Recruiting,No Results Available,Melanoma|Non-Small Cell Lung Cancer|Bladder Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Renal Cancer|Head and Neck Cancer|Other Solid Cancers,Drug: RO7198457|Drug: Atezolizumab,"Genentech, Inc.|Biontech RNA Pharmaceuticals GmbH",All,"18 Years and older ï_ (Adult, Senior)",572,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO39733|2017-001475-23,null,"Percentage of Participants with Dose-Limiting Toxicities (DLTs)|MTD/Recommended Phase 2 Dose (RP2D) of RO7198457|Percentage of Participants with Adverse Events (AEs) by Severity According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Percentage of Participants with Immune-Mediated Adverse Events (imAEs) by Severity According to NCI CTCAE Version 4.0|Percentage of Participants by Number of Treatment Cycles Received|Dose Intensity of RO7198457|Plasma Concentration of (R)-N,N,N-Trimethyl-2,3-Dioleyloxy-1-Propanaminium Chloride (DOTMA)|Plasma Concentration of Ribonucleic Acid (RNA)|Serum Concentration of Atezolizumab|Percentage of Participants with Induction of Antigen-Specific T-Cell Responses in Peripheral Blood|Immune-Related Cytokine Levels|Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Response (DoR) According to RECIST v1.1|Percentage of Participants with Objective Response of CR or PR According to Immune-Modified RECIST|DoR According to Immune-Modified RECIST|Progression-Free Survival (PFS) According to RECIST v1.1|Overall Survival (OS)|Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab",,https://ClinicalTrials.gov/show/NCT03289962
clinicaltrials.gov,rociletinib,1271035,P00533,"InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)",HUFOZJXAKZVRNJ-UHFFFAOYSA-N,COc1cc(ccc1Nc2ncc(c(Nc3cccc(NC(=O)C=C)c3)n2)C(F)(F)F)N4CCN(CC4)C(=O)C,atezolizumab,NA,Q9NZQ7,,,,,lung cancers,Phase 1/2,NA,,NCT02630186,A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer,Drug: Rociletinib|Drug: MPDL3280A,"Clovis Oncology, Inc.|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,CO-1686-032,null,Nov-12,"Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v4.03|Maximum concentration (Cmax) of rociletinib and its metabolites|Time to maximum concentration (Tmax) for rociletinib and rociletinib metabolites|Minimum concentration (Cmin) of rociletinib and metabolites|Area under the curve (AUC) of rociletinib and rociletinib metabolites|Maximum concentration (Cmax) of MPDL3280A|Minimum concentration (Cmin) of MPDL3280A|Objective response rate per RECIST v1.1 in Phase 2|Objective response rate per modified RECIST v1.1, incorporating immune-related criteria, in Phase 2|Duration of response per RECIST v1.1 and modified RECIST v1.1, incorporating immune-related criteria, in Phase 2|Progression-free survival per RECIST v1.1 and modified RECIST v1.1, incorporating immune-related criteria, in Phase 2|Overall survival|Longitudinal changes in blood based biomarkers (eg, mutations in EGFR) in ctDNA",https://ClinicalTrials.gov/show/NCT02630186
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,avelumab,NA,Q9NZQ7,,,,,kidney cancers,Phase 2,NA,,NCT03341845,Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC,Not yet recruiting,No Results Available,Renal Cell Carcinoma,Drug: Axitinib|Drug: Avelumab,The Netherlands Cancer Institute|Pfizer,All,"18 Years and older ï_ (Adult, Senior)",40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N17JAV,null,number of patients with partial remission|toxicity|event free survival and overall survival,,https://ClinicalTrials.gov/show/NCT03341845
clinicaltrials.gov,Debio 1143,NA,,,,,avelumab,NA,Q9NZQ7,,,,,lung cancers,Phase 1,NA,,NCT03270176,A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung|Neoplasms",Drug: Debio 1143|Drug: Avelumab,Debiopharm International SA,All,"18 Years and older ï_ (Adult, Senior)",61,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Debio 1143-NSCLC-105,null,Part A: Maximum Tolerated Dose (MTD)|Part B: Objective Response Rate (ORR)|Part A and B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part A and B: Change in Tumor Size|Part A and B: Objective Response Rate|Part A and B: Best Overall Response (BOR)|Part A and B: Duration of Response|Part A and B: Disease Control Rate|Part A and B: Progression Free Survival (PFS)|Part A and B: Overall Survival (OS)|Part A and B: Assessment of Pharmacokinetic Parameters,,https://ClinicalTrials.gov/show/NCT03270176
clinicaltrials.gov,defactinib,1369032,Q05397;Q14289,"InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)",FWLMVFUGMHIOAA-UHFFFAOYSA-N,CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(=O)(=O)C)n2)C(F)(F)F)cc1,avelumab,NA,Q9NZQ7,,,,,ovarian cancers,Phase 1,NA,,NCT02943317,"Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial ovarian Cancers",Recruiting,No Results Available,Epithelial ovarian Cancers,Drug: Part A - VS-6063|Drug: Part A - Avelumab,"Verastem, Inc.",Female,"18 Years and older __ (Adult, Senior)",98,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,VS-6063-107,null,Oct-14,Number of Participants taking defactinib in combination with avelumab with Adverse Events as a Measure of Safety and Tolerability|maximum tolerated dose (MTD) of defactinib in combination with avelumab (Part A)|best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Part B)|time to treatment response disease control|best overall response according to immune-related response evaluation criteria in solid tumors (irRECIST)|immune related progression-free survival (irPFS) time according to irRECIST and RECIST v1.1|progression-free survival (PFS) time according to irRECIST and RECIST v1.1|overall Survival (OS)|duration of response (DOR) according to irRECIST and RECIST v1.1|plasma concentration of avelumab and defactinib,https://ClinicalTrials.gov/show/NCT02943317
clinicaltrials.gov,eFT508,NA,,,,,avelumab,NA,Q9NZQ7,,,,,colorectal cancers,Phase 2,NA,,NCT03258398,A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,Recruiting,No Results Available,Microsatellite Stable Relapsed or Refractory Colorectal Cancer,Drug: eFT508|Drug: Avelumab,Effector Therapeutics|Merck KGaA|Pfizer,All,"18 Years and older ï_ (Adult, Senior)",70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,eFT508-0006,null,Part 1: Proportion of subjects with a dose limiting toxicity (DLT) during the first treatment cycle|Part 2: Overall Response Rate,,https://ClinicalTrials.gov/show/NCT03258398
clinicaltrials.gov,PT-112,NA,,,,,avelumab,NA,Q9NZQ7,,,,,lung cancers;bladder cancers;head and neck cancers;breast cancers;prostate cancers,Phase 1/2,NA,,NCT03409458,A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab,Not yet recruiting,No Results Available,Non Small Cell Lung Cancer (NSCLC)|Urothelial Carcinoma (UC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Metastatic Breast Cancer (mBC)|Castration-resistant Prostate Cancer (CRPC),Drug: PT-112|Biological: avelumab,Phosplatin Therapeutics|Pfizer|EMD Serono,All,"18 Years and older ï_ (Adult, Senior)",52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PT-112-103-PAVE-1,PAVE-1,Recommended dose (RD) of PT-112 to be used in combination with avelumab for further studies in patients with advanced solid tumors.|Peak Plasma concentration (Cmax) for PT-112 Injection|Area under the plasma concentration versus time curve (AUC) for PT-112 Injection|Dose-limiting toxicities (DLTs)|Number of patients with Adverse Events (AEs)|Tumor burden Assessment|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Median Progression-free Survival (mPFS),,https://ClinicalTrials.gov/show/NCT03409458
clinicaltrials.gov,TG4001,NA,,,,,avelumab,NA,Q9NZQ7,,,,,head and neck cancers,Phase 1/2,NA,,NCT03260023,Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN,Recruiting,No Results Available,Head and Neck Squamous Cell Carcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Carcinoma,Biological: TG4001|Drug: Avelumab,"Transgene|Merck KGaA|EMD Serono Research & Development Institute, Inc.|Pfizer",All,"18 Years and older ï_ (Adult, Senior)",52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TG4001.12,null,Phase Ib: To evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies|Phase II: To evaluate the efficacy of TG4001 combined to avelumab in terms of Overall Response Rate (ORR) by using RECIST 1.1 in the expansion cohort of oropharyngeal recurrent or metastatic (R/M) SCCHN|Overall response rate (ORR)|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of overall Response (DoR)|Disease control rate (DCR)|Incidence of Adverse Event reported per CTCAE v4.03,,https://ClinicalTrials.gov/show/NCT03260023
clinicaltrials.gov,valporic acid,382,P51649,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,avelumab,NA,Q9NZQ7,,,,,cervical cancers;female cancers;male cancers;other,Phase 2,NA,,NCT03357757,Avelumab With Valproic Acid in Virus-associated Cancer,Recruiting,No Results Available,Cancer That is Associated With a Chronic Viral Infection|p16 Positive SCCHN|Squamous Cell Carcinoma of the Cervix|p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva|p16 Positive Squamous Cell Carcinoma of the Penis|p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal|EBER Positive NPC|EBER Positive Hodgkins and Non-hodgkins Lymphona,Drug: Valproic Acid|Biological: Avelumab,AHS Cancer Control Alberta|EMD Serono,All,"18 Years and older ï_ (Adult, Senior)",39,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LATENT,LATENT,Efficacy of Avelumab and VPA|Proportion of subjects who complete 4 doses of Avelumab in combination with VPA|Overall survival|Progression free survival|Number of participants with adverse events|Identify specific virus-associated cancers as candidates for subsequent study|Measurement of Immuno-score|Measurement of MHC expression|Measurement of cell-free tumoral DNA in blood|Phenotyping of Tumour Infiltrating Lymphocytes|DNA viral load|Expression of lytic viral genes|Cytotoxic T-Lymphocyte immunophenotyping|T-cell receptor sequencing|Hsp90 concentration in serum,,https://ClinicalTrials.gov/show/NCT03357757
clinicaltrials.gov,avelumab,NA,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1,NA,,NCT02493751,A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100),Recruiting,No Results Available,Renal Cell Cancer,Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736),Pfizer,All,"18 Years and older __ (Adult, Senior)",55,Industry,Interventional,Masking: No masking|Primary Purpose: Treatment,B9991002|2015-001137-25|Javelin Renal 100,null,Mar-14,Number of participant with Dose-Limiting Toxicities (DLT)|Number of participants with Objective Response|Duration of response (DR)|Progression Free Survival (PFS)|Time to Response (TTR)|Maximum plasma concentration (Cmax) of MSB0010718C (avelumab)|Maximum plasma concentration (Cmax) of axitinib|Time to reach the maximum plasma concentration (Tmax) of axitinib|Trough plasma concentration (Ctrough) of MSB0010718C (avelumab)|AUC0-tau is the area under the curve from time 0 to next dose for axitinib|Elimination half-life (t1/2) of axitinib|Tumor tissue biomarkers|Anti-Drug Antibody (ADA) levels of MSB0010718C/Neutralizing antibodies titers for MSB0010718C|Disease Control (DC)|Overall Survival,https://ClinicalTrials.gov/show/NCT02493751
clinicaltrials.gov,avelumab,NA,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,liver cancers,Phase 1,NA,,NCT03289533,A Study Of Avelumab In Combination With Axitinib In Advanced HCC,Recruiting,No Results Available,"Carcinoma, Hepatocellular",Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736),Pfizer,All,"20 Years and older ï_ (Adult, Senior)",20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B9991024,null,"Adverse events (AEs) and laboratory abnormalities as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.|Time to Progression (TTP)|Overall Survival (OS)|Maximum plasma concentration (Cmax) of avelumab|Maximum plasma concentration (Cmax) of axitinib|Tumor tissue biomarker status (ie, positive or negative based on, for example, PD-L1 expression and/or quantitation of tumor infiltrating CD8+ T lymphocytes as assessed by immunohistochemistry [IHC]).|Anti drug antibodies (ADAs, neutralizing antibodies [nAbs]) for avelumab when in combination with axitinib.|Progression Free Survival (PFS)|Objective Response (OR)|Time to Tumor Response (TTR)|Duration of Response (DR)|Trough plasma concentration (Ctrough) of avelumab|Trough plasma concentration (Ctrough) of axitinib|Disease Control (DC)",,https://ClinicalTrials.gov/show/NCT03289533
clinicaltrials.gov,nivolumab,NA,Q15116,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1/2,NA,,NCT03172754,Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,Recruiting,No Results Available,Renal Cell Carcinoma,Drug: Nivolumab|Drug: Axitinib,Fox Chase Cancer Center,All,"18 Years and older ï_ (Adult, Senior)",98,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GU-102,null,Incidence of treatment-related adverse events|Overall response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Safety profile as assessed by CTCAE 4.03|PD-L1 expression on tumor biospecimens|Tumor infiltrating lymphocyte assessments on tumor biospecimens|Pharmacodynamic effect of study treatment including cytokines,,https://ClinicalTrials.gov/show/NCT03172754
clinicaltrials.gov,X4P-001,NA,,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1/2,NA,,NCT02667886,Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,Recruiting,No Results Available,Clear Cell Renal Cell Carcinoma,Drug: X4P-001|Drug: axitinib,X4 Pharmaceuticals,All,"18 Years and older __ (Adult, Senior)",83,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,X4P-001-RCCA,null,Feb-15,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)|Objective Response Rate|Disease Control Rate|Progression Free Survival|Maximum Plasma Concentration (Cmax)|Area Under the Curve (AUC)|Minimum Plasma Concentration (Cmin),https://ClinicalTrials.gov/show/NCT02667886
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,AZD-5363,NA,P31751;Q9Y243;P31749,"InChI=1S/C32H44F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-6,9-10,20-22,24,28,30-31H,4,7-8,11-19H2,1-3H3/t24?,30?,31-/m1/s1",AESXAJXKMUNYJP-ZWFIUULVSA-N,CCN(C1CCN(CC[C@H](C2CCC(CC2)S(=O)(=O)C)c3cc(F)cc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,,advanced solid cancers,Phase 1,NA,,NCT02338622,Trial of Olaparib in Combination With AZD5363 (ComPAKT),Unknown status,No Results Available,Advanced Cancer,Drug: olaparib|Drug: AZD5363,"Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom|AstraZeneca",All,"18 Years and older __ (Adult, Senior)",58,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCR4058|2013-004692-13,ComPAKT,Sep-11,"Safety/tolerability of olaparib in combination with AZD5363|Maximum tolerated dose and recommended Phase II dose of this combination in patients with advanced solid tumours.|Plasma levels of olaparib and AZD5363 using validated assays.|pAkt/Akt, pGSK/GSK3, pS6 kinase/S6 kinase and pPRAS40/PRAS40 ratios in pre- and post-treatment tumour biopsies using validated assays.",https://ClinicalTrials.gov/show/NCT02338622
clinicaltrials.gov,durvalumab,NA,Q9NZQ7,,,,bavituximab,NA,,,,,,lung cancers,Phase 2,NA,,NCT02673814,Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer,Withdrawn,No Results Available,Non-Small Cell Lung Cancer,Biological: durvalumab|Biological: bavituximab,Peregrine Pharmaceuticals,All,"18 Years and older __ (Adult, Senior)",0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PPHM 1501,null,Mar-13,Objective Response Rate (ORR),https://ClinicalTrials.gov/show/NCT02673814
clinicaltrials.gov,amcasertib,1896288,,"InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-",QDWKGEFGLQMDAM-ULJHMMPZSA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(cc23)c4csc(n4)c5ccccc5)c1C,BBI503,NA,,,,,,advanced solid cancers,Phase 1,NA,,NCT02432326,A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,Recruiting,No Results Available,Cancer|Advanced Solid Tumors,Drug: BBI608|Drug: BBI503,"Boston Biomedical, Inc",All,"18 Years and older __ (Adult, Senior)",150,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,BBI401-101,null,Sep-13,"Determination of the safety and tolerability of BBI608 and BBI503 when administered in combination by assessing dose-limiting toxicities (DLTs)|Determination of the Recommended Phase 2 Dose of BBI608 and BBI503 when administered in combination based on DLT criteria, pharmacokinetic/pharmacodynamic observations and tolerability overall|Pharmacokinetic profile of BBI608 and BBI503 when administered in combination as assessed by maximum plasma concentration and area under the curve.|Pharmacodynamic activity assessed by tumor biopsy|Assessment of the preliminary anti-tumor activity by performing tumor assessments",https://ClinicalTrials.gov/show/NCT02432326
clinicaltrials.gov,carfilzomib,134643,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,belinostat,73864,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",NCNRHFGMJRPRSK-MDZDMXLPSA-N,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc2ccccc2,,lymphoma,Phase 1,NA,,NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,Recruiting,No Results Available,Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma,Drug: Carfilzomib|Drug: Belinostat,Massachusetts General Hospital|National Comprehensive Cancer Network,All,"18 Years and older __ (Adult, Senior)",30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,14-096,null,Sep-13,Maximum tolerated doses of carfilzomib and belinostat in combination|Number of Participants with Serious Adverse Events|Plasma Concentration Time Profiles|Objective response rate,https://ClinicalTrials.gov/show/NCT02142530
clinicaltrials.gov,alectinib,859887,Q9UM73;P07949,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)N6CCOCC6,bevacizumab,11,P15692,,,,,lung cancers,Phase 1/2,NA,,NCT02521051,"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",Recruiting,No Results Available,Non-Small Cell Lung Cancer (NSCLC),Drug: Alectinib|Drug: Bevacizumab,"Massachusetts General Hospital|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",43,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,15-055,null,Sep-14,"Recommended phase II dose of the combination of Alectinib and Bevacizumab|Number of participants treated with the combination of alectinib and bevacizumab with adverse events|Central nervous system objective response rate|Central nervous system disease control rate|Central nervous system progression-free survival|Overall objective response rate|Overall disease control rate|Progression-free survival|Quality of life: change from baseline to on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30|Quality of life: change from baseline and on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-BN20|Number of patients with an ALK resistance mutation",https://ClinicalTrials.gov/show/NCT02521051
clinicaltrials.gov,AMG 386,NA,Q15389;O15123,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,NA,,NCT01290263,Amgen 386 for Recurrent Glioblastoma,Completed,Has Results,Glioblastoma Multiforme,Drug: Amgen 386|Drug: Bevacizumab,Dana-Farber Cancer Institute|Amgen,All,"18 Years and older __ (Adult, Senior)",48,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,12-185,null,Jun-11,6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B]|AMG 386 Maximum Tolerated Dose (MTD) [Cohort B Phase I]|AMG 386 Dose Limiting Toxicity (DLT) [Cohort B Phase I]|Best Radiographic Response [Cohort A and Cohort B]|Overall Survival (OS) [Cohort A and Cohort B]|Progression-Free Survival (PFS) [Cohort A and Cohort B],https://ClinicalTrials.gov/show/NCT01290263
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,bevacizumab,11,P15692,,,,,colorectal cancers,Phase 2,NA,,NCT03271255,Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C),Not yet recruiting,No Results Available,Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms,Drug: Apatinib Mesylate Tablets|Drug: Bevacizumab Injection,Shenzhen People's Hospital,All,"18 Years to 70 Years ï_ (Adult, Senior)",80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Shenzhen CRC-001,null,Progression-free Survival (PFS) Time|Overall Survival (OS)|Percentage of Participants Achieving an Objective Response (Objective Response Rate)|Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate),,https://ClinicalTrials.gov/show/NCT03271255
clinicaltrials.gov,atezolizumab,NA,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bladder cancers,Phase 2,NA,,NCT03133390,Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,Not yet recruiting,No Results Available,Urothelial Carcinoma,Drug: Atezolizumab 1200 mg|Drug: Bevacizumab 15 mg/kg IV,New York University School of Medicine,All,"18 Years to 75 Years __ (Adult, Senior)",118,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,16-01918,null,Apr-14,Overall Survival|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (ORR + SD)|Progression-Free Survival (PFS),https://ClinicalTrials.gov/show/NCT03133390
clinicaltrials.gov,atezolizumab,NA,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bladder cancers,Phase 2,NA,,NCT03272217,Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer,Recruiting,No Results Available,Urothelial Carcinoma,Drug: Atezolizumab|Drug: Bevacizumab,"Arjun Balar, MD|Roche-Genentech|Hoosier Cancer Research Network",All,"18 Years and older ï_ (Adult, Senior)",118,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCRN GU15-215,null,Overall survival (OS)|Objective response rate (ORR)|Duration of Response (DoR)|Disease Control Rate|Progression-Free Survival (PFS)|Assess Safety and Toxicity by CTCAEv4,,https://ClinicalTrials.gov/show/NCT03272217
clinicaltrials.gov,atezolizumab,NA,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bowel cancers,Phase 2,NA,,NCT02982694,"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer",Not yet recruiting,No Results Available,"MSI|ColoRectal Cancer|Chemotherapy|Resistance, APC",Drug: Atezolizumab|Drug: Bevacizumab,Vall d'Hebron Institute of Oncology|European Organisation for Research and Treatment of Cancer - EORTC,All,"18 Years and older __ (Adult, Senior)",58,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,VHIO16001 - EORTC 1604|2016-002001-19,null,Feb-15,Overall Response Rate|Immune-related tumor response|Progression Free Survival|Overall Survival|Safety and tolerability (adverse event assessment according to CTCAE v 4.0),https://ClinicalTrials.gov/show/NCT02982694
clinicaltrials.gov,BEVZ92,NA,,,,,bevacizumab,11,P15692,,,,,bowel cancers,Phase 1,NA,,NCT02069704,Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN__) in First-line Treatment mCRC Patients,"Active, not recruiting",No Results Available,Metastatic Colorectal Cancer,"Drug: Bevacizumab biosimilar (BEVZ92)|Drug: Avastin__ (bevacizumab, reference product)",mAbxience S.A|Laboratorio Elea S.A.C.I.F. y A.|Libbs Farmac_utica Ltda,All,"18 Years and older __ (Adult, Senior)",142,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BEVZ92-A-01-13,null,Sep-11,"To compare the PK profile of BEVZ92 and Avastin__, both administered in combination with FOLFOX (any) or FOLFIRI|Safety, immunogenicity and efficacy profile",https://ClinicalTrials.gov/show/NCT02069704
clinicaltrials.gov,capmatinib,1278782,P08581,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2,bevacizumab,11,P15692,,,,,brain cancers;bowel cancers;kidney cancers,Phase 1,NA,,NCT02386826,INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme,Recruiting,No Results Available,Glioblastoma Multiforme|Gliosarcoma|Colorectal Cancer|Renal Cell Carcinoma,Drug: INC280|Biological: bevacizumab,"SCRI Development Innovations, LLC|Novartis",All,"18 Years and older __ (Adult, Senior)",63,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,SCRI REFMAL 365,null,Aug-14,Maximum Tolerated Dose (MTD) of INC280|Progression-free Survival|Overall Response Rate,https://ClinicalTrials.gov/show/NCT02386826
clinicaltrials.gov,cetuximab,9,P00533,,,,bevacizumab,11,P15692,,,,,head and neck cancers,Phase 2,NA,,NCT00409565,A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer,Completed,Has Results,Head and Neck Cancer|Squamous Cell Carcinoma,Drug: Cetuximab|Drug: Bevacizumab,National Cancer Institute (NCI),All,"18 Years to 98 Years __ (Adult, Senior)",48,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,NCI-2009-00171|NCI / CTEP Protocol # 7440,null,Jan-08,Objective Response Rate (ORR)|Progression-free Survival (PFS)|Overall Survival (OS)|Change in Serum Cytokine Concentrations|Disease Control Rate (DCR) ((Clinical Benefit Rate (CBR)),https://ClinicalTrials.gov/show/NCT00409565
clinicaltrials.gov,CRLX101,NA,,,,,bevacizumab,11,P15692,,,,,kidney cancers,Phase 1,NA,,NCT01625936,CRLX101 Plus Bevacizumab in Advanced RCC,"Active, not recruiting",No Results Available,Renal Cell Carcinoma,Drug: CRLX101 (Cerulean)|Drug: Bevacizumab,Abramson Cancer Center of the University of Pennsylvania,All,"18 Years and older __ (Adult, Senior)",22,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment,UPCC 02812,null,May-10,Number of Adverse Events,https://ClinicalTrials.gov/show/NCT01625936
clinicaltrials.gov,DSP-7888,NA,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 2,NA,,NCT03149003,A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy,Recruiting,No Results Available,Glioblastoma Multiforme,Drug: DSP-7888 Dosing Emulsion|Drug: Bevacizumab,"Boston Biomedical, Inc",All,"18 Years and older __ (Adult, Senior)",200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,BBI-DSP7888-201G,WIZARD201G,Nov-15,Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)|Overall Survival|Twelve-month Survival|Progression Free Survival|Six-month Progression Free Survival|Response Rate|Duration of Response|Number of Patients with Adverse Events,https://ClinicalTrials.gov/show/NCT03149003
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,bowel cancers,Phase 3,NA,,NCT00598156,Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva,Completed,No Results Available,Metastatic Colorectal Cancer,Drug: erlotinib (Tarceva)|Drug: bevacizumab (Avastin),Lund University Hospital|Hoffmann-La Roche,All,"18 Years and older __ (Adult, Senior)",249,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ML19033|EUDRACT 2006-002295-18,ACT,Sep-05,progression-free survival|overall survival,https://ClinicalTrials.gov/show/NCT00598156
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,NA,,NCT00193154,OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma,Completed,No Results Available,Kidney Cancer,Drug: OSI-774|Drug: Bevacizumab,"SCRI Development Innovations, LLC|AstraZeneca|Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",63,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI GU 17|AVF2488s,null,Dec-99,Efficacy of the combination of Tarceva and Avastin|Objective response rate|Progression-free survival|Overall Survival|Overall tolerability and toxicity of this combination regimen,https://ClinicalTrials.gov/show/NCT00193154
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,NA,,NCT01562028,BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC),"Active, not recruiting",No Results Available,Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,European Thoracic Oncology Platform|Spanish Lung Cancer Group,All,"18 Years and older __ (Adult, Senior)",110,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ETOP 2-11 / MO27911|2011-004481-15|MO27911,BELIEF,Sep-13,Progression free survival|Time to treatment failure|Objective response|Toxicity|Disease control|Duration of response|Overall survival (OS),https://ClinicalTrials.gov/show/NCT01562028
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,NA,,NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Nave Non-Small Cell Lung Cancer,Completed,Has Results,Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,"Nasser Hanna, M.D.|Genentech, Inc.|Walther Cancer Institute|Hoosier Cancer Research Network",All,"18 Years and older __ (Adult, Senior)",25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HOG LUN04-77,null,Mar-04,To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician|Time to Progression|Overall Survival,https://ClinicalTrials.gov/show/NCT00367601
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,NA,,NCT00749567,Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer,Terminated,No Results Available,Non-small-cell Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years and older __ (Adult, Senior)",13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CT/08.15,null,Aug-06,Overall response rate|Progression Free Survival|Overall Survival|Quality of life assessment|Toxicity profile,https://ClinicalTrials.gov/show/NCT00749567
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,NA,,NCT02633189,Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer,Recruiting,No Results Available,Non-squamous Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,"National Cancer Institute, Naples",All,"18 Years to 70 Years __ (Adult, Senior)",200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,BEVERLY|2015-002235-17,BEVERLY,Nov-13,"progression free survival|overall survival|changes in quality of life scores from baseline|number of patients with complete and partial responses , investigator assessed|number of patients with complete and partial responses , centrally reviewed|worst grade toxicity per patient|progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)",https://ClinicalTrials.gov/show/NCT02633189
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,mesothelioma,Phase 2,NA,,NCT00137826,Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma,Completed,No Results Available,Mesothelioma,Drug: Erlotinib|Drug: Bevacizumab,Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago,All,"18 Years and older __ (Adult, Senior)",37,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,03-369,null,Feb-03,To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma|To determine the time to tumor progression|to determine the duration of response|to determine the median and overall survival of patients|to determine the safety of the drugs administered,https://ClinicalTrials.gov/show/NCT00137826
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,oesophageal cancers,Phase 2,NA,,NCT00442507,Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction,Terminated,Has Results,Esophageal Neoplasms|Esophageal Diseases,Drug: Erlotinib|Drug: Avastin,Washington University School of Medicine,All,"18 Years and older __ (Adult, Senior)",6,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,06-1105,OSI3650,Dec-04,"Time to Progression (TTP)|Overall Survival Rate (OS)|Response Rate (Complete Response (CR), Partial Response (PR), and CR+PR)|Incidence and Severity of Toxicities",https://ClinicalTrials.gov/show/NCT00442507
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,NA,,NCT00651482,Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus),Terminated,Has Results,Kidney Neoplasms|Kidney (Renal Cell) Cancer,Drug: Everolimus|Drug: Bevacizumab,"Sandy Srinivas|Genentech, Inc.|Novartis|Stanford University",All,"18 Years and older __ (Adult, Senior)",10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,IRB-11789|RENAL0016|98593|AVF4304s|41839,null,Feb-08,Progression-free Survival (PFS)|Objective Response (OR)|Objective Response (OR) Duration|Time-to-Treatment Failure (TTF)|Overall Survival (OS)|Number of Subjects With Drug-related SAEs|Total Number of Drug-related SAEs|Treatment Discontinuation Due to Toxicity|Treatment Discontinuation Due to Disease Progression,https://ClinicalTrials.gov/show/NCT00651482
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,other;soft tissue cancers,Phase 2,NA,,NCT01661283,SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,"Active, not recruiting",No Results Available,Malignant Peripheral Nerve Sheath Tumors|MPNST|Sarcoma,Drug: everolimus|Drug: bevacizumab,"Sarcoma Alliance for Research through Collaboration|Novartis Pharmaceuticals|Genentech, Inc.|United States Department of Defense",All,"18 Years and older __ (Adult, Senior)",25,Other|Industry|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SARC016,null,May-13,Evaluation of lesions for progression or response via Who criteria,https://ClinicalTrials.gov/show/NCT01661283
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,ovarian cancers;female cancers,Phase 2,NA,,NCT01031381,"Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",Completed,Has Results,ovarian Cancers|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Drug: RAD001|Drug: bevacizumab,"University of Pittsburgh|Novartis Pharmaceuticals|Genentech, Inc.",Female,"18 Years and older __ (Adult, Senior)",50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-01-RAD001BEV,RADBEV,Dec-09,Progression-free Survival (PFS) at 6-months|Total Number of Participants Experienced a Response (Complete Response+Partial Response+Stable Disease),https://ClinicalTrials.gov/show/NCT01031381
clinicaltrials.gov,EZN-2208,NA,,,,,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,NA,,NCT01251926,EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors,Completed,No Results Available,Neoplasms,Drug: EZN-2208|Drug: Bevacizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 120 Years __ (Adult, Senior)",12,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,110042|11-C-0042,null,null,"Determine the modulation of HIF-1Alpha protein (by ELISA) in solid tumors after treatment with EZN-2208 and bevacizumab.|Determine the safety and tolerability of the combination of EZN-2208 and bevacizumab with EZN-2208 administered weekly times 3 (Days 1, 8, and 15) and bevacizumab administered every 2 weeks in 28-day cycles.",https://ClinicalTrials.gov/show/NCT01251926
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,bevacizumab,11,P15692,,,,,breast cancers,Phase 2,NA,,NCT00444535,Lapatinib and Bevacizumab for Metastatic Breast Cancer,"Active, not recruiting",Has Results,"Neoplasms, Breast",Drug: lapatinib|Drug: bevacizumab,Novartis Pharmaceuticals|Novartis,Female,"18 Years and older __ (Adult, Senior)",50,Industry,Interventional,Masking: No masking|Primary Purpose: Treatment,EGF103890,null,"July 22, 2008",Percentage of Participants Reaching Week 12 Without Disease Progression|Overall Response|Clinical Benefit|Progression-free Survival,https://ClinicalTrials.gov/show/NCT00444535
clinicaltrials.gov,MIL60,NA,,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,NA,,NCT03196986,MIL60 Versus Bevacizumab in Patients With Treatment-nave Non-squamous Non-small Cell Lung Cancer,Not yet recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: MIL60|Drug: Bevacizumab,"Beijing Mabworks Biotech Co., Ltd.",All,"18 Years to 75 Years __ (Adult, Senior)",436,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment",MIL60-CT02,null,Apr-15,Objective response rate|Disease control rate|Progression-free survival,https://ClinicalTrials.gov/show/NCT03196986
clinicaltrials.gov,MINT1526A,NA,,,,,bevacizumab,11,P15692,,,,,,Phase 1,NA,,NCT01139723,"A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",Completed,No Results Available,Solid Cancers,Drug: MINT1526A|Drug: bevacizumab,"Genentech, Inc.",All,"18 Years and older __ (Adult, Senior)",54,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MNT4863g|GO00808,null,Jul-10,"Incidence and nature of dose-limiting toxicities (DLTs)|Incidence, nature, and severity of adverse events and serious adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0|Pharmacokinetic parameters of MINT1526A (including total exposure, maximum and minimum serum concentration, clearance, volume of distribution at steady state)",https://ClinicalTrials.gov/show/NCT01139723
clinicaltrials.gov,MRZ,539795,,"InChI=1S/C6H13N3/c7-6(8)9-4-2-1-3-5-9/h1-5H2,(H3,7,8)",QUUYRYYUKNNNNS-UHFFFAOYSA-N,NC(=N)N1CCCCC1,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,NA,,NCT02330562,Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab,Recruiting,No Results Available,Malignant Glioma|Glioblastoma,Drug: MRZ|Drug: BEV,Triphase Research and Development I Corporation,All,"18 Years and older __ (Adult, Senior)",106,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,MRZ-108,null,Sep-13,"Part 1 (Phase 1): Maximum Tolerated Dose (MTD) / Maximum Administered Dose (MAD)|Part 1 (Phase 1): Recommended Phase 2 Dose (RP2D)|Part 2 (Phase 2): MRZ single agent tumor activity|Part 3 (Phase 2): activity of MRZ + BEV with intra-patient dose escalation|Part 1 (Phase 1): Tumor activity|Parts 1, 2 & 3 (Phase 1 and Phase 2): Assess safety and tolerance|Part 1 (Phase 1): MRZ pharmacokinetics|Part 1 (Phase 1): Proteasome Activity in Packed Whole Blood (PWB)|Parts 1, 2 & 3 (Phase 1 and Phase 2): Neurological Coordination Assessment|Parts 1, 2 & 3 (Phase 1 and Phase 2): Quality of Life Assessment",https://ClinicalTrials.gov/show/NCT02330562
clinicaltrials.gov,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,bevacizumab,11,P15692,,,,,kidney cancers;bowel cancers;lung cancers;ovarian cancers;cervical cancers,Phase 1,NA,,NCT02835833,Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,Recruiting,No Results Available,Renal Cell Carcinoma|Colorectal Adenocarcinoma|Non-squamous Non-small Cell Lung Cancer|Platinum-refractory Ovarian Carcinoma|Cervical Carcinoma,Drug: Nintedanib|Drug: Bevacizumab,University of Alabama at Birmingham|Boehringer Ingelheim,All,"19 Years and older __ (Adult, Senior)",8,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,F160202011 (UAB 15108),null,Nov-15,Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerable dose of Nintedanib|Objective tumor response rate|Progression-free survival|Plasma level of vascular endothelial growth factor (VEGF)|Plasma level of platelet-derived growth factor (PDGF)|Plasma level of vascular endothelial growth factor and receptor (VEGF-R)|Plasma level of phosphatidylinositol-glycan biosynthesis class F protein (PIGF)|Plasma level of fibroblast growth factor (FGF),https://ClinicalTrials.gov/show/NCT02835833
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,bevacizumab,11,P15692,,,,,ovarian cancers,Phase 1/2,NA,,NCT02354131,Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial ovarian Cancers,Recruiting,No Results Available,ovarian Cancers,Drug: Niraparib|Drug: Bevacizumab,"Nordic Society for Gynaecologic Oncology|ENGOT|GCIG|University of Utah|Massachusetts General Hospital|Myriad Genetics, Inc.",Female,"18 Years and older __ (Adult, Senior)",108,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,ENGOT-OV24-NSGO/AVANOVA,AVANOVA,Oct-14,Progression free survival|Disease Control Rate,https://ClinicalTrials.gov/show/NCT02354131
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,bevacizumab,11,P15692,,,,,ovarian cancers;female cancers,Phase 2,NA,,NCT03326193,"Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",Recruiting,No Results Available,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Drug: Niraparib|Biological: Bevacizumab,"Tesaro, Inc.",Female,"18 Years and older ï_ (Adult, Senior)",90,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3000-02-004,null,Assessment of Efficacy|Clinical Benefit - Progression Free Survival (PFS) by RECIST v 1.1|Clinical Benefit - Overall Survival (OS) by patient assessment|Clinical Benefit - RECIST or CA-125 PFS by RECIST v .1.1 or CA-125 measurement using Gynecologic Cancer Intergroup (GCIG) criteria.|Clinical Benefit - Patient Reported Outcome (PRO) - Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI)|Clinical Benefit - Time to First Subsequent Therapy (TFST)|Clinical Benefit - Time to Second Subsequent Therapy (TSST)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,https://ClinicalTrials.gov/show/NCT03326193
clinicaltrials.gov,nivolumab,NA,Q15116,,,,bevacizumab,11,P15692,,,,,liver cancers,Phase 1,NA,,NCT03382886,Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma,Not yet recruiting,No Results Available,Hepatocellular Carcinoma,Drug: Nivolumab|Drug: Bevacizumab,University of Utah|Bristol-Myers Squibb,All,"18 Years and older ï_ (Adult, Senior)",12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCI103945,NUANCE,Adverse Events that occur|Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)|Progression Free Survival (PFS)|Overall Survival,,https://ClinicalTrials.gov/show/NCT03382886
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,NA,,NCT00710268,Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours,Completed,No Results Available,Neoplasm Metastasis,Drug: AZD2281|Drug: Bevacizumab,AstraZeneca,All,"18 Years and older __ (Adult, Senior)",18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D0810C00022,null,Feb-05,"safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with Bevacizumab to patients with advanced solid tumours by assessment of adverse events, vital signs, ECG, clinical chem, haematology, urinalysis and phys exam|To compare exposure to AZD2281 when given alone and in combination with Bevacizumab, by assessment of appropriate derived PK parameters",https://ClinicalTrials.gov/show/NCT00710268
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,bevacizumab,11,P15692,,,,,lung cancers,Phase 1/2,NA,,NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,Recruiting,No Results Available,Non-small Cell Lung Cancer|EGFR-mutant Lung Cancers,Drug: osimertinib|Drug: Bevacizumab,"Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc.",All,"19 Years and older __ (Adult, Senior)",58,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,16-033,null,May-15,maximum tolerated dose (MTD) (Phase I)|progression-free survival (Phase II),https://ClinicalTrials.gov/show/NCT02803203
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,NA,,NCT00859222,LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma,Completed,Has Results,Malignant Glioma,Drug: LBH589|Drug: bevacizumab,"Patrick Y. Wen, MD|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Northwestern University|University of Virginia|Genentech, Inc.|Novartis|Dana-Farber Cancer Institute",All,"18 Years and older __ (Adult, Senior)",51,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,08-342|CLBH589BUS42T,null,Aug-09,LBH589 Maximum Tolerated Dose (MTD) [Phase I]|Dose Limiting Toxicity (DLT) [Phase I]|6-Month Progression-Free Survival (PFS6) [Phase II]|Best Radiographic Response|Progression-Free Survival (PFS) [Phase II]|Overall Survival [Phase II],https://ClinicalTrials.gov/show/NCT00859222
clinicaltrials.gov,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,bevacizumab,11,P15692,,,,,,Phase 1,NA,,NCT00781846,Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED),Completed,No Results Available,Solid Tumor,Drug: ridaforolimus|Drug: bevacizumab,Merck Sharp & Dohme Corp.|Ariad Pharmaceuticals,All,"18 Years and older __ (Adult, Senior)",17,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,8669-010|AP23573-08-111,null,Jan-06,Identification of recommended phase 2 dose of ridaforolimus in combination with bevacizumab|Characterize the overall safety and tolerability of ridaforolimus in combination with bevacizumab|Description of the anti-tumor activity of ridaforolimus in combination with bevacizumab,https://ClinicalTrials.gov/show/NCT00781846
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,bevacizumab,11,P15692,,,,,liver cancers,Phase 1,NA,,NCT00467194,Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Completed,No Results Available,Liver Cancer,Drug: Rapamycin|Drug: Bevacizumab,"National Cancer Centre, Singapore",All,"18 Years and older __ (Adult, Senior)",27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000540163|SINGAPORE-06-17-HEP,null,Apr-07,"Dose-limiting toxicity|Maximum tolerated dose|Response rate (complete and partial response and stable disease)|Progression-free survival|Overall survival|Distribution of p70S6K activity in peripheral blood mononuclear cells|Correlation of p70S6K with tumor response|Expression of tumor tissue biomarkers (PTEN, 4EBP-1, CD31, p70S6K, and vascular endothelial growth factor)|Correlation of tumor biomarkers with response|Best overall response (complete and partial response; stable and progressive disease)|Change in DCE-CT scan assessment of angiogenesis",https://ClinicalTrials.gov/show/NCT00467194
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,NA,,NCT00556205,Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma,Withdrawn,No Results Available,Renal Cell Carcinoma,Drug: Sunitinib|Drug: Bevacizumab,Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Pfizer,All,"18 Years and older __ (Adult, Senior)",0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,07-202,null,Aug-05,To determine the time to tumor progression (TTP) in this patient population treated with bevacizumab or combination of sunitinib and bevacizumab.|To determine the overall response rate in this patient population.|To evaluate the safety and tolerability of these treatments in mRCC patients with disease progression on standard dose sunitinib.|To collect serum research samples for analysis of predictive biomarkers of response.,https://ClinicalTrials.gov/show/NCT00556205
clinicaltrials.gov,TPI 287,NA,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,NA,,NCT01933815,Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,Recruiting,No Results Available,Glioblastoma Multiforme,Drug: TPI 287|Drug: Bevacizumab,"Cortice Biosciences, Inc.",All,"18 Years and older __ (Adult, Senior)",92,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,TPI-287-17,null,Jan-14,"Phase 1: Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 1: MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by median PFS|Phase 1: Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation and TMZ as measured by median progression free survival (PFS), overall response rate, & progression free survival rate at 4 & 6 months (PFS4 & PFS6)|Phase 2: Safety of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by overall survival and overall response rate",https://ClinicalTrials.gov/show/NCT01933815
clinicaltrials.gov,TPI 287,NA,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 2,NA,,NCT02047214,Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,Terminated,No Results Available,Glioblastoma Multiforme,Drug: TPI 287|Drug: Bevacizumab,"Cortice Biosciences, Inc.",All,"18 Years and older __ (Adult, Senior)",17,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TPI-287-18,null,Nov-11,"Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab|Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by median progression free survival (PFS), overall response rate, & PFS rate at 4 & 6 months (PFS4 & PFS6)",https://ClinicalTrials.gov/show/NCT02047214
clinicaltrials.gov,TPI 287,NA,,,,,bevacizumab,11,P15692,,,,,brain cancers;central nervous system cancers,Phase 1/2,NA,,NCT01582152,Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma,Completed,No Results Available,Brain Neoplasms|Central Nervous System Neoplasms,Drug: TPI287|Drug: Bevacizumab,"M.D. Anderson Cancer Center|Cortice Biosciences, Inc.",All,"18 Years and older __ (Adult, Senior)",12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,2011-0705|NCI-2012-00846,null,Feb-12,Progression Free Survival (PFS)|Objective Response Rate (ORR),https://ClinicalTrials.gov/show/NCT01582152
clinicaltrials.gov,valporic acid,382,P51649,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,bevacizumab,11,P15692,,,,,,Phase 1,NA,,NCT00530907,Valproic Acid and Bevacizumab in Patients With Advanced Cancer,Completed,No Results Available,Advanced Cancer,Drug: Valproic Acid|Drug: Bevacizumab,M.D. Anderson Cancer Center,All,"Child, Adult, Senior",71,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0676,null,Oct-09,Highest tolerable dose of bevacizumab in combination with valproic acid,https://ClinicalTrials.gov/show/NCT00530907
clinicaltrials.gov,VGX-100,NA,,,,,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,NA,,NCT01514123,Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Neoplasms|Cancer,Drug: VGX-100|Drug: Bevacizumab,Circadian Technologies Ltd.,All,"18 Years and older __ (Adult, Senior)",40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,VGX-100-1001,null,Aug-13,"The incidence and severity of adverse events including dose limiting toxicities|Tumor response by RECIST criteria|Pharmacokinetic parameters of VGX-100 alone and co-administered with bevacizumab including Cmax, Cmin, AUC and if feasible half life (t1/2)|Anti-VGX-100 antibody formation|Biomarker levels including VEGF-A, VEGF-C, VEGF-D, soluble VEGFR-2, and soluble VEGFR-3",https://ClinicalTrials.gov/show/NCT01514123